menu

PROTECT Study in IgAN: Topline Data

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

PROTECT Study in IgAN: Topline Data

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The two-year final analysis of the PROTECT trial showed sustained proteinuria reduction and one of the slowest rates of kidney function decline observed in IgAN trials in patients treated with sparsentan, non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA), versus irbesartan, an angiotensin II receptor blocker, highlighting sparsentan’s promising impact on preserving kidney function in patients with IgAN. Your patients will thank you for joining our expert, Dr. Jonathan Barratt in this PROTECT topline data analysis.

  • Provider(s)/Educational Partner(s)

      

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum. 

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The two-year final analysis of the PROTECT trial showed sustained proteinuria reduction and one of the slowest rates of kidney function decline observed in IgAN trials in patients treated with sparsentan, non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA), versus irbesartan, an angiotensin II receptor blocker, highlighting sparsentan’s promising impact on preserving kidney function in patients with IgAN. Your patients will thank you for joining our expert, Dr. Jonathan Barratt in this PROTECT topline data analysis.

  • Provider(s)/Educational Partner(s)

      

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum. 

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

Facebook Comments

Schedule24 May 2024